ClinicalTrials.gg
CompletedNCT02245451Updated Sep 19, 2014

Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers

A Phase 1 interventional study of Tipranavir and Ritonavir in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-19.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The primary objective of this study is to characterise the effects of tipranavir 500 mg and ritonavir 200 mg (TPV/r; given twice daily) at steady-state on the pharmacokinetics of methadone administered as a single dose in healthy adult volunteers

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female healthy volunteers aged at least 18 to 60 years.
  • Clinically normal medical history.
  • Clinically normal findings on physical examination.
  • Clinically normal laboratory values.
  • A >18.5 and \<30 kg/m2.
  • Able to swallow large capsules without difficulty.
  • Capable of comprehending and communicating effectively with the investigator and staff and of providing written in accordance with ethics committee and regulatory guidelines.
  • Willing to stay in the study centre for the duration of the study.
  • Willing to abstain from ingesting substances during the study which may alter plasma study drug levels by interaction with the cytochrome P450 system.
  • Willing to abstain from alcohol for 48 hours prior to Visit 1 and for the duration of the study. In addition, Cabernet Sauvignon must not have been ingested within 15 days prior to Visit 1.
  • Willing to abstain from ingesting grapefruit and grapefruit juice for 15 days before Visit 1 and for the duration of the study.
  • Willing to abstain from ingesting Seville oranges, strawberries or strawberry extract, garlic supplements, St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc) for 72 hours before the pharmacokinetic sampling days.
  • Willing to abstain from use of tobacco products for the duration of the study.
  • Urine drug screen negative for illegal non-prescription drugs.
  • Negative serology.
  • Negative for surface antigen and

Exclusion criteria

Exclusion Criteria:

  • Any disease. (A significant disease was defined as a disease which in the opinion of the investigator may either have put the subject at risk because of participation in the study or a disease which may have influenced the results of the study or the subject's ability to participate in the study.)
  • Clinically significant abnormal baseline haematology, blood chemistry or urinalysis findings.
  • Serum (ALT), aspartate aminotransferase (AST), cholesterol, triglyceride or glucose greater than the at Visit 1.
  • Treatment with prohibited medications in the thirty days before the study or during the study or ingestion of drugs of abuse.
  • Treatment with any drug within 90 days of the first dose of study medication.
  • Inability to adhere to the requirements of the protocol (including active substance abuse) as assessed by the investigator.
  • Prior tipranavir use.
  • Ingestion of any known enzyme altering drug (such as phenothiazines, cimetidine, barbiturates, ketoconazole, fluconazole, clarithromycin, rifampin, , and herbal medications) for thirty days prior to Visit 1.
  • Ingestion of grapefruit, grapefruit juice, and Cabernet Sauvignon within fifteen days prior to Visit 1.
  • Ingestion of Seville oranges, strawberries or strawberry extract, garlic supplements, St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc) within 72 hours of pharmacokinetics sampling days.
  • Treatment with prescription medicines within thirty days prior to Visit 1.
  • History of gastrointestinal, hepatic, or renal disorders within 60 days prior to Visit 1.
  • Any history of alcohol or drug abuse.
  • Current use of cigarettes defined as greater than 10 cigarettes per day or rolling/pipe tobacco equivalent.
  • Blood or plasma donations within 90 days prior to Visit 1
  • Subjects with a seated systolic blood pressure either \<100 mm Hg or >150 mm Hg; resting heart rate either \<50 beats/min or >100 beats/min.
  • Subjects with a history of any illness or allergy that, in the opinion of the investigator, might have confounded the results of the study or posed additional risk in administering tipranavir, ritonavir or methadone to the subject.
  • Subjects who had an acute illness within two weeks prior to Visit 1.
  • Subjects who were currently taking any over-the-counter drug within fourteen days prior to Visit 1 or who were currently taking any prescription drug.
  • to tipranavir, ritonavir, or methadone.
  • Female subjects who are of and who were pregnant, breastfeeding, had a positive serum B-HCG at Visit 1 or 2, had not been using a barrier method for at least three months prior to Study Day 1 or were not willing to use a reliable method of double-barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam) during the study and for thirty days after completion or termination of the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    TPV/r with methadone

    Drug: Tipranavir · Drug: Ritonavir · Drug: Methadone

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve for 0 to 24 hours (AUC0-24h) of methadone

    Time frame: up to 24 hours after drug administration

  2. Maximum concentration (Cmax)

    Time frame: up to 24 hours after drug administration

  3. Concentration at 6 hours (C6h) of methadone

    Time frame: 6 hours after drug administration

  4. Area under the concentration-time curve for 0 to 12 hours (AUC0-12h) of tipranavir and ritonavir

    Time frame: up to 12 hours after drug administration

  5. concentration at 12 hours (C12h) of tipranavir and ritonavir

    Time frame: 12 hours after drug administration

Secondary outcomes

  1. mean residence time (MRT)

    Time frame: up to 24 hours after drug administration

  2. apparent terminal half-life (t½)

    Time frame: up to 24 hours after drug administration

  3. time to maximum concentration (Tmax)

    Time frame: up to 24 hours after drug administration

  4. oral clearance (CL/F)

    Time frame: up to 24 hours after drug administration

  5. apparent volume of distribution during the terminal elimination phase divided by the bioavailability factor (Vz/F)

    Time frame: up to 24 hours after drug administration

  6. Number of patients with abnormal findings in physical examination

    Time frame: Up to day 17 after first drug administration

  7. Number of patients with clinically significant changes in vital signs

    Time frame: Up to day 17 after first drug administration

  8. Number of patients with abnormal changes in clinical laboratory parameters

    Time frame: Up to day 17 after first drug administration

  9. Number of participants with adverse events

    Time frame: Up to day 17 after first drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005 and a primary completion of Feb 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2014
First posted
Sep 19, 2014
Start
Jan 2005
Primary completionActual
Feb 2005
Last update
Sep 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02245451
Responsible party
Sponsor
First posted
Sep 19, 2014
Start date
Jan 2005
Primary completion
Feb 2005
Last update
Sep 19, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tipranavir · Ritonavir · Methadone

Start the discussion